Cytokinetics Inc (CYTK)
Cytokinetics, Incorporated is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators and muscle inhibitors for debilitating diseases. The company markets MYQORZO, an oral small molecule cardiac myosin inhibitor approved for symptomatic oHCM, and is also developing Aficamten for HCM and omecamtiv mecarbil for heart failure with severely reduced ejection fraction. Its pipeline further includes Ulacamten, being studied in Phase 1 clinical trials for heart failure with preserved ejection fraction, and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Founded in 1997, Cytokinetics is headquartered in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CYTK
|
$70.31
|
-12.9% Downside
|
Fair
|
$107.80
|
33.5% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-13.2x
|
-13.3x
|
103.7x
|
10.741 B
|
11.345 B
|
11.8%
|
99.5%
|
-2.0
|
—
|
66.2%
|
